Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
| PAA | PharmAust enters option to license agreement with Elanco | PRICE SENSITIVE | 18/04/18 | |
| PAA | Trading Halt | PRICE SENSITIVE | 16/04/18 | |
| PAA | Wayne Best appointed Epichem Chairman and Dr Keenan as CEO | 10/04/18 | ||
| PAA | Cleansing Notice | 20/03/18 | ||
| PAA | Change of Director's Interest Notice x 3 | 16/03/18 | ||
| PAA | Appendix 3B & s708 notice | 16/03/18 | ||
| PAA | Collaboration with Olivia Newton-John Cancer Research Inst | 14/03/18 | ||
| PAA | Appendix 4D and Half Yearly Report & Accounts | PRICE SENSITIVE | 28/02/18 | |
| PAA | PharmAust receives $354k R&D Tax Incentive Refund | PRICE SENSITIVE | 28/02/18 | |
| PAA | Results of General Meeting | 26/02/18 | ||
| PAA | Monepantel reformulation successfully improves dose & taste | PRICE SENSITIVE | 30/01/18 | |
| PAA PharmAust enters option to license agreement with Elanco | |||
| 18/04/18 | PRICE SENSITIVE | ||
| PAA Trading Halt | |||
| 16/04/18 | PRICE SENSITIVE | ||
| PAA Wayne Best appointed Epichem Chairman and Dr Keenan as CEO | |||
| 10/04/18 | |||
| PAA Cleansing Notice | |||
| 20/03/18 | |||
| PAA Change of Director's Interest Notice x 3 | |||
| 16/03/18 | |||
| PAA Appendix 3B & s708 notice | |||
| 16/03/18 | |||
| PAA Collaboration with Olivia Newton-John Cancer Research Inst | |||
| 14/03/18 | |||
| PAA Appendix 4D and Half Yearly Report & Accounts | |||
| 28/02/18 | PRICE SENSITIVE | ||
| PAA PharmAust receives $354k R&D Tax Incentive Refund | |||
| 28/02/18 | PRICE SENSITIVE | ||
| PAA Results of General Meeting | |||
| 26/02/18 | |||
| PAA Monepantel reformulation successfully improves dose & taste | |||
| 30/01/18 | PRICE SENSITIVE | ||
